Market reference for how much does a box of Anamorelin cost?

Anamorelin (Anamorelin) is an oral small molecule drug that was launched earlier in Japan. It is mainly used to improve appetite loss and weight loss caused by cachexia in cancer patients. Since the drug has not yet been officially approved for marketing in mainland China, if domestic patients currently need to use it, they generally obtain it through overseas medical channels or cross-border pharmacies. Therefore, the price will be affected by exchange rates, channel fees and supply conditions.

The original drug of Anamorelin is developed and produced by Japan's Otsuka Pharmaceutical (Otsuka Pharmaceutical). The common specifications are 50 mg per tablet and 100 tablets in a box. According to data from Japanese pharmacies and cross-border drug sales websites, the price of original drugs fluctuates around 4,000 yuan. The specific price will vary slightly with exchange rate changes and transportation cost adjustments.

If you choose the overseas generic version, the price is more cost-effective. At present, the generic drug of Anamorelin produced by Lucius Pharmaceutical Factory in Laos is relatively common in the international market, and its ingredients are consistent with the original drug, which is also Anamorelin hydrochloride. This imitation version usually sells for about 2,000 to 2,500 yuan per box, which may fluctuate slightly depending on the purchase channel and bulk purchase.

Because Anamorelin is a new type of Ghrelin receptor agonist and has a unique effect on improving cancer cachexia, so the demand continues to grow globally. At present, except Japan, some countries have launched expanded use plans for nutritional support and improvement of life quality of specific tumor patients. When purchasing drugs overseas, patients should pay attention to verify the legality of the source of the drugs, and try to choose regular pharmacies registered with the official drug administration to avoid purchasing informal products with substandard quality.

Overall, the market price of anamorelin is still relatively high, but since there is no direct alternative drug for cancer cachexia, clinical demand is still growing steadily. If it is approved for marketing in China and included in the medical insurance catalog in the future, the price is expected to be further reduced, thereby benefiting more patients with cachexia.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/